Neuroone Medical Technologies (NMTC) Gross Margin (2011 - 2026)

Neuroone Medical Technologies (NMTC) has reported Gross Margin for 11 consecutive years, with 59.94% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Gross Margin rose 600.0% year-over-year to 59.94%; the trailing twelve-month figure through Jun 2026 stood at 55.65% (down 98.0% YoY), and the FY2025 full-year result was 56.51%, up 2525.0% from the prior year.
• Gross Margin climbed to 59.94% in Q2 2026 per NMTC's latest filing, from 53.18% in the prior quarter.
• Across five years, Gross Margin topped out at 59.94% in Q2 2026 and bottomed at 99.01% in Q1 2022.
• Historically, Gross Margin has averaged 25.16% across 5 years, with a median of 36.41% in 2023.
• The sharpest annual moves came in 2023 and 2025: Gross Margin jumped 10577 bps in 2023, then tumbled 465 bps in 2025.
• Over 5 years, Gross Margin stood at 10.74% in 2022, then soared by 354 bps to 27.24% in 2023, then soared by 116 bps to 58.85% in 2024, then fell by 8 bps to 54.2% in 2025, then climbed by 11 bps to 59.94% in 2026.
• According to Business Quant data, Gross Margin over the past three periods registered 59.94%, 53.18%, and 54.2% for Q2 2026, Q1 2026, and Q4 2025 respectively.